Bone Regeneration with Wharton's Jelly-Bioceramic-Bioglass Composite

Publication date: 2015 Source:Procedia Materials Science, Volume 9 Author(s): C.A. Fernández , C.A. Martínez , M.O. Prado , D. Olmedo , A. Ozols The aim of this development is to optimize a bone substitute (BS) for use in tissue engineering. This is achieved through the combination of three phases in a biocomposite (BCO), in which each is reabsorbed in the site of implantation and replaced by autologous bone (patient's own). The inorganic phases are composed of irregular particles (150-300 microns) obtained by milling and sieving of a biphasic bioceramic (BC) of hydroxyapatite (HA of bovine origin) with 40% (wt.) β-tricalcium phosphate (β- TCP, obtained by chemical synthesis) and Bioglass type 45S5 (45SiO2 -24,5CaO - 24,5Na2O - 6P2O5, in % wt.). Instead, the organic phase consists of collagen extracted from Wharton's jelly (part of the human embryonic tissue) from physical and chemical self-developed process. The BC is produced by mixture of HA and β-TCP (< 45μm) and molding by gelcasting with albumin in aqueous solutions, drying and sintering at 1200°C for 2hours. The BG is obtained from the mixture of the oxides, melting at 1350°C and cast onto metal. Each phase and BCO is subjected to studies by electron microscopy (SEM and EDS), X-ray diffraction (DRX) and infrared spectrometry (FT-IR). The biocompatibility is evaluated by in vivo studies using the laminar implant model in Wistar rats (n=40). Histological samples show high biocompatibility and abil...
Source: Procedia Materials Science - Category: Materials Science Source Type: research